150 related articles for article (PubMed ID: 10804327)
1. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context.
Allenet B; Parée F; Lebrun T; Carr L; Posnett J; Martini J; Yvon C
Diabetes Metab; 2000 Apr; 26(2):125-32. PubMed ID: 10804327
[TBL] [Abstract][Full Text] [Related]
2. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers.
Dougherty EJ
Adv Skin Wound Care; 2008 Dec; 21(12):568-75. PubMed ID: 19065083
[TBL] [Abstract][Full Text] [Related]
3. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products.
Gilligan AM; Waycaster CR; Landsman AL
J Wound Care; 2015 Mar; 24(3):149-56. PubMed ID: 25764960
[TBL] [Abstract][Full Text] [Related]
4. Treatment of venous leg ulcers with Dermagraft.
Omar AA; Mavor AI; Jones AM; Homer-Vanniasinkam S
Eur J Vasc Endovasc Surg; 2004 Jun; 27(6):666-72. PubMed ID: 15121121
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
[TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of Apligraf treatment of diabetic foot ulcers.
Redekop WK; McDonnell J; Verboom P; Lovas K; Kalo Z
Pharmacoeconomics; 2003; 21(16):1171-83. PubMed ID: 14594438
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.
Marston WA; Hanft J; Norwood P; Pollak R;
Diabetes Care; 2003 Jun; 26(6):1701-5. PubMed ID: 12766097
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of three adjunct cellular/tissue-derived products used in the management of chronic venous leg ulcers.
Carter MJ; Waycaster C; Schaum K; Gilligan AM
Value Health; 2014 Dec; 17(8):801-13. PubMed ID: 25498775
[TBL] [Abstract][Full Text] [Related]
9. A multidisciplinary diabetic foot protocol at Chiang Mai University Hospital: cost and quality of life.
Rerkasem K; Kosachunhanun N; Tongprasert S; Guntawongwan K
Int J Low Extrem Wounds; 2009 Sep; 8(3):153-6. PubMed ID: 19703951
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
11. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers.
Gentzkow GD; Iwasaki SD; Hershon KS; Mengel M; Prendergast JJ; Ricotta JJ; Steed DP; Lipkin S
Diabetes Care; 1996 Apr; 19(4):350-4. PubMed ID: 8729158
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model.
Castelli C; Combescure C; Foucher Y; Daures JP
Stat Med; 2007 Dec; 26(30):5557-71. PubMed ID: 18058847
[TBL] [Abstract][Full Text] [Related]
13. A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers.
Landsman AS; Cook J; Cook E; Landsman AR; Garrett P; Yoon J; Kirkwood A; Desman E
Foot Ankle Spec; 2011 Feb; 4(1):29-41. PubMed ID: 21135263
[TBL] [Abstract][Full Text] [Related]
14. A Cost-Effectiveness Analysis Comparing Single-use and Traditional Negative Pressure Wound Therapy to Treat Chronic Venous and Diabetic Foot Ulcers.
Kirsner RS; Delhougne G; Searle RJ
Wound Manag Prev; 2020 Mar; 66(3):30-36. PubMed ID: 32294054
[TBL] [Abstract][Full Text] [Related]
15. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer.
Marston WA
Expert Rev Med Devices; 2004 Sep; 1(1):21-31. PubMed ID: 16293007
[TBL] [Abstract][Full Text] [Related]
16. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
[TBL] [Abstract][Full Text] [Related]
17. The costs and benefits of enhanced depression care to employers.
Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
[TBL] [Abstract][Full Text] [Related]
18. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
Langer A; Rogowski W
BMC Health Serv Res; 2009 Jul; 9():115. PubMed ID: 19591680
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U; Willis M; Odegaard K; Apelqvist J
Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
